ELSEVIER

Drug and Alcohol Dependence 60 (2000) 329–331

DRUG and ALCOHOL DEPENDENCE

www.elsevier.com/locate/drugalcdep

Cumulative Author index

Volumes 57–60 (2000)

Abood, M.E. **60**, 133
Adams, E.H. **57**, 7
Addy, R.C. **59**, 177
Adlaf, E.M. **60**, 97
Albery, I.P. **58**, 197
Alcorn, R. **59**, 189
Alemán-Valls, M.R. **59**, 295
Ali, S.F. **59**, 143
Alterman, A.I. **59**, 215
Alterman, A.I. **60**, 267
Amass, L. **58**, 143
Angelopoulos, E.K. **59**, 95
Anglin, M.D. **57**, 137
Anthony, J.C. **57**, 183
Anthony, J.C. **59**, 89
Anthony, J.C. **60**, 251
Anton, R.F. **60**, 161
Ator, N.A. **57**, 51
Aung, M.M. **60**, 133
Averill, P.M. **60**, 189
Aykaç-Toker, G. **58**, 77

Babb, D.A. **60**, 69
Badger, G.J. **60**, 259
Bailley, S.E. **60**, 189
Balldin, J. **57**, 255
Ball, S.A. **57**, 225
Balster, R.L. **58**, 1
Bammer, G. **58**, 173
Barber, J.P. **60**, 169
Bass, C.E. **60**, 113
Batlle, F. **59**, 223
Battisson, L. **58**, 173
Battjes, R.J. **57**, 81
Baumann, M.H. **59**, 143
Bearn, J. **59**, 183
Bearn, J. **60**, 207
Ben-Abdallah, A. **58**, 247
Benowitz, N.L. **60**, 13
Berggren, U. **57**, 255
Best, D. **60**, 319
Bickel, W.K. **58**, 27
Bickel, W.K. **60**, 259
Bienkowski, P. **60**, 199
Bigelow, G.E. **58**, 205
Bisaga, A. **59**, 1
Bishop, S. **60**, 169
Blaine, J. **59**, 63, 77
Blow, F.C. **58**, 43
Bobashev, G. **60**, 251
Bondarev, M. **57**, 1
Booth, R.E. **58**, 219
Bortone, L. **58**, 93
Brady, K.T. **59**, 277
Brady, K.T. **60**, 161
Brodsky, A. **60**, 221
Broers, B. **58**, 85
Broome, K.M. **57**, 113, 127
Brown, B.S. **57**, 137
Brown, M. **60**, 151
Brown, S. **60**, 69
Bucholz, K.K. **60**, 295
Bukstein, O.G. **59**, 173
Buntwal, N. **59**, 183

Cacciola, J.S. **59**, 215
Calay, Z. **58**, 77
Carboni, E. **58**, 93
Carmen del Río, M. **57**, 177
Carpenter, K.M. **59**, 63, 77
Carrieri, M.P. **60**, 51
Carrigan, M.H. **59**, 277
Carroll, K.M. **57**, 225
Casas, M. **59**, 223
Cedeño, M. **60**, 251
Cherek, D.R. **60**, 179
Chermack, S.T. **58**, 43
Chermack, S.T. **59**, 43
Childress, A.R. **59**, 33
Chioni, A. **59**, 95
Chitwood, D.D. **58**, 153, 219
Christo, G. **59**, 189
Chutuape, M.A. **57**, 211
Cicero, T.J. **57**, 7
Clapp, J.D. **60**, 19
Cnaan, A. **59**, 215
Coffey, S.F. **59**, 277
Cofrancesco, J. **60**, 311
Compton, W. **57**, 203
Compton, W.M. **58**, 215, 247
Cone, E.J. **58**, 205
Conte, G. **59**, 287
Copeland, A.L. **59**, 17
Copeland, J. **59**, 309
Copeland, J. **60**, 91
Corey, L.A. **57**, 69
Cornish, J.W. **59**, 33
Costantino, L. **60**, 121
Cottler, L.B. **57**, 203
Cottler, L.B. **58**, 247
Craddock, S.G. **57**, 99
Crits-Christoph, P. **60**, 169
Crome, I.B. **59**, 207
Crosby, H. **58**, 227
Crowley, T.J. **59**, 131
Crystal, S. **60**, 77
Cunningham, J.A. **59**, 211
Cunningham-Williams, R. **58**, 247

Dadds, M.R. **60**, 1
Daley, D. **60**, 169
Dansky, B.S. **59**, 277
Darke, S. **58**, 189
Darke, S. **60**, 141
Daskalopoulou, E.G. **59**, 95
Davis, K. **60**, 121
Davis, L. **59**, 43
Dawe, S. **60**, 1
Dawson, D.A. **59**, 235
Degenhardt, L. **57**, 247
de la Vega-Prieto, M.J. **59**, 295
Dellamonica, P. **60**, 51
Delva, J. **59**, 89
Delva, J. **60**, 251
Dennis, M.L. **58**, 259
De Risio, S. **59**, 287
de Wit, H. **59**, 251
Di Chiara, G. **58**, 93
DiClemente, C.C. **59**, 177
Dietz Trautman, K. **59**, 77
Dillon, P. **60**, 91
Dobs, A.S. **60**, 311
Doğru-Abbasoğlu, S. **58**, 77
Dolan, R.J. **60**, 207
Douglas Anglin, M. **57**, 151
Dudish-Poulsen, S. **57**, 239
Dukat, M. **60**, 121
Dumont, P. **58**, 85

Eber, M. **58**, 227
Egan, C. **60**, 121
Ehlers, C.L. **58**, 125
Ehlers, K.M. **59**, 131
Ehrman, R.N. **59**, 33
Epperson, L. **60**, 267
Etcheberrigaray, A. **59**, 223
Etheridge, R.M. **57**, 99

PII: S0376-8716(00)00202-7

Fahlke, C. **57**, 255
Farbiszewski, R. **57**, 61
Farren, C.K. **59**, 153
Fenton, L. **57**, 225
Fletcher, B.W. **57**, 81
Floyd, K. **60**, 319
Flynn, P.M. **57**, 167
Frackowiak, R.S.J. **60**, 207
France, C.P. **59**, 51
Franken, I.H.A. **59**, 305
Frankforter, T.L. **57**, 225
Friston, K.J. **60**, 207
Fudala, P.J. **60**, 29
Fujimura, R.K. **58**, 153
Fuller, B.E. **58**, 43
Furr, C.D.M. **59**, 89

Gallais, H. **60**, 51
Gallop, R. **60**, 169
Gariti, P. **60**, 267
Gastfriend, D.R. **60**, 169
Gatzonis, S.D. **59**, 95
Geller, A. **57**, 7
Geppetti, P. **60**, 13
Gessa, G.L. **60**, 39
Ghodse, A.H. **58**, 111
Giner, F. **58**, 85
Giua, C. **58**, 93
Glass, Y. **59**, 207
Glennon, R.A. **57**, 1
Glennon, R.A. **60**, 121
Gómez-Rodríguez, M.A. **59**, 295
González, G. **60**, 251
González, I. **58**, 159
González-Reimers, E. **59**, 295
Gossop, M. **57**, 89
Gossop, M. **58**, 165, 197
Gossop, M. **59**, 183
Gossop, M. **60**, 275
Goto, K. **58**, 67
Grabowski, J. **59**, 43
Grabowski, J. **60**, 189
Graham, G. **58**, 153
Grant, B.F. **60**, 287
Greeley, J.D. **57**, 29
Greenwald, M.K. **59**, 261
Grella, B. **60**, 121
Grella, C.E. **57**, 137, 151
Griffin, G. **60**, 133
Griffin, M.L. **60**, 169
Griffith, J.D. **58**, 55
Griffiths, P. **58**, 197
Griffiths, R.R. **57**, 51
Grimm, J.W. **57**, 41
Gruber, K. **57**, 211

Habrat, B. **60**, 199
Hall, W. **57**, 247
Hall, W. **59**, 309
Hameedi, F.A. **59**, 153
Harnett, P.H. **60**, 1
Hasin, D.S. **59**, 63, 77
Hatsukami, D.K. **57**, 239
Hatsukami, D.K. **60**, 69
Hatzimanolis, J. **57**, 261
Heishman, S.J. **60**, 29
Hendriks, V.M. **59**, 305
Hennen, J. **58**, 35
Henningfield, J.E. **60**, 29
Herron, J. **60**, 161
Hettema, J.M. **57**, 69
Higgins, S.T. **58**, 103
Hock, C. **57**, 23
Hoffman, J.A. **58**, 227
Hollister, L.E. **58**, 3
Hong, S.-S. **60**, 121
Horton, J. **57**, 203
Howlett, M. **58**, 111
Hser, Y.-I. **57**, 137, 151
Hsieh, S.-C. **57**, 137
Hubbard, R.L. **57**, 99, 167
Huffman, J.W. **60**, 133
Hug, I. **57**, 23

Iguchi, M.Y. **57**, 193
Ikemoto, S. **58**, 67
Inciardi, J.A. **57**, 7
Ishiguro, T. **58**, 67
Ivis, F.J. **60**, 97

Jacob, P., III **60**, 13
Jatlow, P. **59**, 153
Javier Alvarez, F. **57**, 177
Joe, G.W. **57**, 113, 127
Johnson, R.E. **60**, 29
Jones, H.E. **60**, 29
Joshi, V. **57**, 151

Kajdasz, D.K. **60**, 161
Kamali, F. **59**, 125
Kamien, J.B. **58**, 143
Kaminska, E. **60**, 303
Katz, E. **58**, 205
Kaufman, M.J. **58**, 35
Kaye, S. **58**, 189
Keel, C. **60**, 133
Kendler, K.S. **57**, 69
Kilaru, U. **59**, 43
Kilpatrick, B. **58**, 111
Klein, H. **58**, 227
Kokkevi, A. **58**, 181
Koros, E. **60**, 199
Kosten, T.R. **59**, 153
Kostowski, W. **60**, 199
Kostrzewa, A. **60**, 303
Kristiansen, P.L. **57**, 167
Krupski, A. **60**, 151
Kruzich, P.J. **57**, 41
Kukes, T.J. **58**, 35
Kukwa, A. **60**, 199
Kwiatkowski, C.F. **58**, 219

Ladewig, D. **57**, 23
Lane, S.D. **60**, 179
Lázaro, M.I. **58**, 159
Lepeu, G. **60**, 51
Leukefeld, C. **58**, 237
Levin, J.M. **58**, 35
Lexau, B. **57**, 239
Logan, T.K. **58**, 237
London, L. **59**, 199
Longhi, D. **60**, 151
Luchansky, B. **60**, 151
Lukas, S. **59**, 165
Lukas, S.E. **58**, 35
Lykouras, L. **57**, 261
Lynch, K.G. **59**, 173
Lynskey, M. **57**, 247

MacDonald, B. **58**, 259
Madden, G.J. **60**, 259
Malcolm, R. **60**, 161
Manning, V. **60**, 319
Mantouvalos, V. **59**, 95
Maremmani, I. **60**, 39
Markianos, M. **57**, 261
Marsden, J. **57**, 89
Marsden, J. **58**, 165
Marsden, J. **60**, 275
Martin, B.R. **60**, 113, 133
Martin, C.S. **59**, 173
Martin, S. **59**, 223
Martínez-Riera, A. **59**, 295
Mattson, M.V. **60**, 121
McCaffrey, D. **57**, 193
McCoy, C.B. **58**, 153
McGill, T. **60**, 55
McKay, J.R. **59**, 215
McNamara, C. **60**, 55
M. Dürsteler, K. **57**, 23
Mendelson, J.H. **58**, 35
Merikle, E.P. **59**, 215
Metsch, L. **58**, 153
Michael, M. **60**, 55
Miele, G.M. **59**, 63, 77
Mikolajczak, P. **60**, 303
Mikulich, S.K. **58**, 143
Mikulich, S.K. **59**, 131
Milby, J.B. **60**, 55
Milena, A. **59**, 295
Mino, A. **58**, 85
Moerschbaecher, J.M. **59**, 51
Morral, A.R. **57**, 193
Morris, J.S. **60**, 207
Moussas, G. **57**, 261
Müller-Spahn, F. **57**, 23
Mulvaney, F.D. **59**, 215
Mulvaney, F.D. **60**, 267
Muñoz, A. **57**, 7
Mutlu-Türkoğlu, Ü. **58**, 77

Neale, J. **58**, 117
Nelson, D. **57**, 239

Nemtsov, A.V. **58**, 133
Newbury-Birch, D. **59**, 125
Nich, C. **57**, 225
Norrby, A. **57**, 255
Nuro, K.F. **57**, 225

Obadia, Y. **60**, 51
O'Brien, C.P. **59**, 33
Odum, A.L. **60**, 259
Ogborne, A. **60**, 315
Okulicz-Kozaryn, I. **60**, 303
Onken, L.S. **60**, 169
Orozco, S. **59**, 165
Öztezcan, S. **58**, 77

Page, J.B. **58**, 153
Pani, P.P. **60**, 39
Parrott, A.C. **60**, 105
Peele, S. **60**, 221
Pentel, P.R. **57**, 239
Pentel, P.R. **60**, 69
Pérez de los Cobos, J. **59**, 223
Pérez-Manzano, J.L. **59**, 295
Perritt, R. **58**, 259
Peters, R. **60**, 91
Petronis, K.R. **57**, 183
Petry, N.M. **58**, 9, 27
Phelps, D.L. **60**, 295
Pirastu, R. **60**, 39
Politikou, K. **58**, 181
Pollock, N.K. **59**, 173
Popik, P. **59**, 1
Porto, J.V. **57**, 167
Pozzi, G. **59**, 287
Preston, K.L. **58**, 205

Queraltó, J.M. **59**, 223

Rasch, R.F.R. **58**, 259
Rawaf, S. **60**, 319
Rehm, J. **60**, 97
Reilly, M. **59**, 43
Renaud, F.L. **58**, 159
Renshaw, P.F. **58**, 35
Rivers, J.E. **58**, 153
Roark, R.R. **58**, 55
Robbins, S.J. **59**, 33
Robles, E. **58**, 205
Rolfe, A. **57**, 89
Rolfe, A. **58**, 165
Rolfe, A. **60**, 275
Roll, J. **59**, 43
Roll, J.M. **58**, 103
Room, R. **60**, 249
Rosen, M.A. **59**, 153
Ross, J. **60**, 141
Rothfleisch, J.M. **60**, 189
Rothman, R.B. **59**, 143
Rounds-Bryant, J.L. **57**, 99
Rounsaville, B.J. **57**, 225
Rowan-Szal, G.A. **58**, 55
Rowley, J. **60**, 319
Rustay, N. **57**, 41
Rutherford, M.J. **59**, 215

Sambamoorthi, U. **60**, 77
Santolaria, F. **59**, 295
Sarr, M. **60**, 295
Sattler-Mayr, J. **57**, 23
Sayre, S.L. **60**, 189
Schmitz, J.M. **60**, 189
Schnoll, S.H. **57**, 7
Schumacher, J.E. **60**, 55
Scinska, A. **60**, 199
Sedgwick, P. **58**, 111
See, R.E. **57**, 41
Segal, D. **58**, 153
Seifritz, E. **57**, 23
Sell, L.A. **60**, 207
Senay, E.C. **57**, 7
Shah Jr, N. **60**, 311
Shah, S.M. **58**, 153
Shapshak, P. **58**, 153
Shillington, A.M. **60**, 19
Showalter, V.M. **60**, 133
Siafakas, A. **59**, 95
Sifry, R.L. **57**, 225
Silverman, K. **58**, 205
Silvester, K.R. **59**, 51
Simpson, D.D. **57**, 113, 127
Simpson, D.D. **58**, 55
Sisk, E. **60**, 105
Skrzydlewska, E. **57**, 61
Slawecki, C.J. **58**, 125
Smart, R.G. **60**, 315
Smith, C. **60**, 121
Smith Cockerham, M. **59**, 63, 77
Sofuoglu, M. **57**, 239
Sofuoglu, M. **60**, 69
Somes, C. **58**, 125
Sorensen, J.L. **59**, 17
Spire, B. **60**, 51
Spitznagel, E.L. **58**, 247
Spurrell, S. **59**, 189
Staiger, P. **60**, 1
Staiger, P.K. **57**, 29
Stark, K. **60**, 151
Stefanis, C. **58**, 181
Stewart, D. **57**, 89
Stewart, D. **58**, 165
Stewart, D. **60**, 275
Stitzer, M.L. **57**, 211
Stitzer, M.L. **58**, 205
Stitzer, M.L. **59**, 261
Stohler, R. **57**, 23
Störmer, R. **57**, 23
Stotts, A.L. **60**, 189
Strang, J. **58**, 197
Strang, J. **59**, 183
Strang, J. **60**, 319
Sunjic, S. **60**, 141
Surratt, H.L. **58**, 267
Swift, W. **59**, 309

Tagliamonte, A. **60**, 39
Tang, A. **60**, 311
Tarter, R.E. **59**, 101
Teitler, M. **60**, 121
Tejero, A. **59**, 223
Terzidou, M. **58**, 181
Tomassini, N. **58**, 159
Tourian, K.A. **59**, 215
Trautman, K.D. **59**, 63
Trujols, J. **59**, 223
Turner, J.J.D. **60**, 105

Usdan, S. **60**, 55
Uysal, M. **58**, 77

Vanyukov, M.M. **59**, 101
Velasquez, M.M. **59**, 177
Villafuerte, R.A. **58**, 35
Vlahov, D. **60**, 51

Wachtel, S.R. **59**, 251
Wahlstrom, J.T. **60**, 311
Walkup, J. **60**, 77
Wallace, D. **60**, 55
Wallace, S.D. **57**, 29
Ward, J. **58**, 173
Warner, L.A. **60**, 77
Weatherby, N. **58**, 153
Wechsberg, W.M. **58**, 259
Weerts, E.M. **57**, 51
Weisen, C.A. **58**, 259
Weiss, R.D. **60**, 169
White, M. **59**, 125
Whitmore, E.A. **59**, 131
Wiktorowicz, K. **60**, 303
Wilson, S. **58**, 173
Winsauer, P.J. **59**, 51
Woods, S. **59**, 153
Woody, G.E. **57**, 7
Wu, M.-J. **60**, 133

Yang, B. **60**, 133
Yang, J. **58**, 153
Young, R. **57**, 1
Yui, K. **58**, 67

Zachrisson, O. **57**, 255
Zador, D. **60**, 141
Zevin, S. **60**, 13
Zournas, C. **59**, 95

ELSEVIER

Drug and Alcohol Dependence 60 (2000) 333–345

DRUG and ALCOHOL DEPENDENCE

www.elsevier.com/locate/drugalcdep

Cumulative Subject index

Volumes 57–60 (2000)

Abstinence; Dopamine; Nicotine; Naloxone; Nucleus accumbens; Prefrontal cortex **58**, 93

Abstinence; Ethanol; Associative learning; Event related potentials; Neurophysiology **58**, 125

Abstinence initiation; Voucher-based reinforcement; Cocaine abuse; Urinalysis; Methadone patients; Contingency contracting **58**, 205

Abuse; Anabolic-androgenic steroids; Dependence; Women **60**, 91

Abuse; Drug self-administration; Propofol; Methohexital; Cocaine; Feeding; Primates **57**, 51

Accident involvement; Illicit drugs; Impaired driving; Impairment beliefs **58**, 197

Acculturation; Drug use; Ethnic; Gender; Aggression **59**, 165

Addiction; Buprenorphine; Methadone maintenance; Heroin **60**, 39

Addiction; Ibogaine; MK-801; Dopamine; Corticosterone; Prolactin **59**, 143

Addiction; Nicotine; Cotinine; Metabolism; Pharmacokinetics; Tobacco; Pharmacodynamics **60**, 13

Addiction severity index; Opioids; Detoxification **58**, 85

Adolescent drug use; Frequent smoking; Frequent drinking; Risk factors; Substance use careers **60**, 319

Adolescents; Conduct disorder; Substance use; Attention-deficit hyperactivity disorder; Major depressive disorder; Gender **59**, 131

Adolescents; Diagnostic interviews; DSM-IV; SCID; Substance use disorders **59**, 173

Adolescents; Substance use reports; Agreement rates; Reliability; Surveys **60**, 19

Adrenergic receptors; Self-administration; Carvedilol; Cocaine; Cardiovascular effects **60**, 69

Affinity; Cannabinoid; Cannabinoid receptors; Radioligand binding; Cannabimimetic indoles; Aminoalkylindoles **60**, 133

African-American; Alcohol; Crack; HIV; Sexual risk **58**, 259

Aftercare; Drug abuse treatment; Outpatient treatment; Heroin; Cocaine; Contingency management; Housing; Employment **57**, 211

Age of onset; Substance use disorders; Personality disorders; Psychopathology; Comorbidity **59**, 305

Aggression; Acculturation; Drug use; Ethnic; Gender **59**, 165

Aggression; Relationships; Alcohol; Drugs; Violence **58**, 43

Agreement rates; Substance use reports; Reliability; Adolescents; Surveys **60**, 19

AIDS; HIV prevention; Drug abuse; Antisocial personality; Depression; Comorbidity **58**, 247

AIDS; Injecting drug user; Blood; Needle/syringe; Paraphernalia; Shooting gallery; HIV-1 RNA load **58**, 153

Alcohol abuse; Alcohol dependence; Dependence symptoms; Diagnosis; Nosology **60**, 295

Alcohol abuse; Alcohol dependence; Subtypes of alcohol dependence; Subtypes of alcohol abuse; Nosology **60**, 287

Alcohol; African-American; Crack; HIV; Sexual risk **58**, 259

Alcohol; Aggression; Relationships; Drugs; Violence **58**, 43

Alcohol; Cocaine; Pergolide; Clinical trial; Pharmacotherapy **60**, 161

Alcohol consumption; CAGE; MAST; DOP system; Farm workers; South Africa **59**, 199

Alcohol consumption; Moderate drinking; Psychosocial models; Mental health; Cognitive performance; Psychological benefits **60**, 221

Alcohol consumption *per capita*; Student drinking; Cross culture comparisons **60**, 315

Alcohol consumption; Russia; Registered and unregistered alcohol consumption; Consequences of alcohol consumption **58**, 133

Alcohol; Cue exposure; Dependent drinkers; Generalisation; Relapse prevention **57**, 29

Alcohol dependence; Alcohol abuse; Dependence symptoms; Diagnosis; Nosology **60**, 295

Alcohol dependence; Alcohol abuse; Subtypes of alcohol dependence; Subtypes of alcohol abuse; Nosology **60**, 287

Alcoholic patients; Dopamine receptor responsivity; Detoxification **57**, 261

PII: S0376-8716(00)00203-9

Alcoholics anonymous; Self-help groups; Cocaine; Treatment; Drug abuse **60**, 169

Alcohol; Illegal drugs; Road traffic accidents; Spain **57**, 177

Alcoholism; Malnutrition; Social problems; Feeding habits; Liver disease; DEXA **59**, 295

Alcohol; Medical students; Illicit drugs; Stress; Personality **59**, 125

Alcohol; NMDA receptor antagonists; Opiates; Psychostimulants; Pharmacotherapy **59**, 1

Alcohol; Substance misuse; Treatment outcomes; Evaluation; Clinical audit **59**, 189

Alcohol withdrawal; Clonidine; Growth hormone; Noradrenergic activity **57**, 255

Alternate-day dosing; Buprenorphine; Buprenorphine–naloxone; Heroin treatment; Human; Methadone treatment **58**, 143

Alternating logistic regression; Epidemiology; Drug use; Panama; Clustering; Schools **60**, 251

Aminoalkylindoles; Cannabinoid; Cannabinoid receptors; Radioligand binding; Affinity; Cannabimimetic indoles **60**, 133

Amphetamine; Ephedrine; Norephedrine; Pseudoephedrine; Cathine; Phenylpropanolamines; Khat; Ma huang; Optical isomers; Ephedra; Herbal dietary supplements; Thermogenic agents **57**, 1

Amphetamines; Heroin; Harms; Injecting drug use **58**, 189

Anabolic-androgenic steroids; Abuse; Dependence; Women **60**, 91

Analgesia; Marijuana smoking; Δ^9-Tetrahydrocannabinol; Antinociception; Endogenous opioids; Naltrexone; Subjective effects; Performance; Heart rate; Humans **59**, 261

Antinociception; Marijuana smoking; Δ^9-Tetrahydrocannabinol; Analgesia; Endogenous opioids; Naltrexone; Subjective effects; Performance; Heart rate; Humans **59**, 261

Antisocial behavior; Risk taking; Drug abuse; Laboratory task **60**, 179

Antisocial personality; HIV prevention; Drug abuse; AIDS; Depression; Comorbidity **58**, 247

Assessment; DSM-IV dependence; Severity; Reliability; Validity; Outcome measures **59**, 63

Assessment; Substance Dependence Severity Scale; Predictive validity **59**, 77

Associative learning; Ethanol; Abstinence; Event related potentials; Neurophysiology **58**, 125

Attention-deficit hyperactivity disorder; Conduct disorder; Substance use; Major depressive disorder; Gender; Adolescents **59**, 131

AUDIT; Survey methods; Epidemiology **60**, 97

Australia; Cannabis; Dependence; Follow-up **59**, 309

Autoremission; Natural recoveries; Drug use; Service utilization **59**, 211

Baseline predictors; Cocaine dependence; Treatment outcome **59**, 215

Behavioral phenotype; Substance abuse; Genotype–environment interaction **59**, 101

Benzodiazepine; Convulsive status epilepticus; Flunitrazepam; Lorazepam; Seizures; Side effects; Withdrawal **59**, 95

Benzodiazepine receptors; β-carbolines; Harmaline; Harmine; Hallucinogens; Dimethyltryptamine (DMT); 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM); Serotonin receptors; Dopamine receptors; PI hydrolysis **60**, 121

Bitter; Ethanol; Taste perception; Sweet; Sour; Humans **60**, 199

Blockade; Nalmefene; Morphine; Subjective effects; Pharmacology **60**, 29

Blood; Injecting drug user; Needle/syringe; Paraphernalia; Shooting gallery; HIV-1 RNA load; AIDS **58**, 153

Blood pressure; Cocaine; Crack cocaine; Cardiovascular response; Heart rate; Toxicity **57**, 239

Brain imaging; Cocaine; Drug history; Intravenous; Safety **58**, 35

Brazil; Cocaine; HIV **58**, 267

Buprenorphine; Alternate-day dosing; Buprenorphine–naloxone; Heroin treatment; Human; Methadone treatment **58**, 143

Buprenorphine; HIV; Injection drug users; Drug maintenance treatment; Viral load **60**, 51

Buprenorphine; Hostility; Retention; Early termination; Gender differences; Heroin; Opioid dependence; Substance abuse treatment **58**, 27

Buprenorphine; Methadone maintenance; Heroin; Addiction **60**, 39

Buprenorphine–naloxone; Alternate-day dosing; Buprenorphine; Heroin treatment; Human; Methadone treatment **58**, 143

Buprenorphine; Opioid dependence; Treatment; Thrice-weekly dosing **59**, 223

CAGE; Alcohol consumption; MAST; DOP system; Farm workers; South Africa **59**, 199

Calcium sequestration; Cocaine; Ethanol; Hepatotoxicity; Lipid peroxidation **58**, 77

Cannabimimetic indoles; Cannabinoid; Cannabinoid receptors; Radioligand binding; Affinity; Aminoalkylindoles **60**, 133

Cannabinoid; Cannabinoid receptors; Radioligand binding; Affinity; Cannabimimetic indoles; Aminoalkylindoles **60**, 133

Cannabinoid; Delta-9-tetrahydrocannabinol; Δ^9-THC; Tolerance; Time course **60**, 113

Cannabinoid; Dronabinol; Marijuana; Opioid; THC **59**, 251

Cannabinoid receptors; Cannabinoid; Radioligand binding; Affinity; Cannabimimetic indoles; Aminoalkylindoles **60**, 133

Cannabis; Dependence; Follow-up; Australia **59**, 309

β-carbolines; Harmaline; Harmine; Hallucinogens; Dimethyltryptamine (DMT); 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM); Serotonin receptors; Dopamine receptors; Benzodiazepine receptors; PI hydrolysis **60**, 121

Cardiovascular effects; Adrenergic receptors; Self-administration; Carvedilol; Cocaine **60**, 69

Cardiovascular response; Cocaine; Crack cocaine; Blood pressure; Heart rate; Toxicity **57**, 239

Carvedilol; Adrenergic receptors; Self-administration; Cocaine; Cardiovascular effects **60**, 69

Cathine; Ephedrine; Norephedrine; Pseudoephedrine; Phenylpropanolamines; Amphetamine; Khat; Ma huang; Optical isomers; Ephedra; Herbal dietary supplements; Thermogenic agents **57**, 1

Cigarette smoking; Contingency-management; Substance abuse; Relapse; Schedules of reinforcement; Treatment **58**, 103

Circadian cycle; Ethanol preference; Rats; Lymphocyte subsets; Cytometry **60**, 303

Clinical audit; Substance misuse; Alcohol; Treatment outcomes; Evaluation **59**, 189

Clinical trial; Cocaine; Pergolide; Alcohol; Pharmacotherapy **60**, 161

Clonidine; Alcohol withdrawal; Growth hormone; Noradrenergic activity **57**, 255

Clonidine; Opiate withdrawal; Naltrexone; Trazodone **59**, 287

Clozapine; Cocaine; Drug interactions; Humans **59**, 153

Clustering; Epidemiology; Drug use; Panama; Alternating logistic regression; Schools **60**, 251

Cocaine abuse; Voucher-based reinforcement; Abstinence initiation; Urinalysis; Methadone patients; Contingency contracting **58**, 205

Cocaine addiction; Drug treatment costs; Treatment benefits; Crime costs; Cost-benefit **57**, 167

Cocaine; Adrenergic receptors; Self-administration; Carvedilol; Cardiovascular effects **60**, 69

Cocaine; Brain imaging; Drug history; Intravenous; Safety **58**, 35

Cocaine; Brazil; HIV **58**, 267

Cocaine; Calcium sequestration; Ethanol; Hepatotoxicity; Lipid peroxidation **58**, 77

Cocaine; Clozapine; Drug interactions; Humans **59**, 153

Cocaine; Crack cocaine; Cardiovascular response; Blood pressure; Heart rate; Toxicity **57**, 239

Cocaine dependence; Baseline predictors; Treatment outcome **59**, 215

Cocaine dependence; Cue reactivity; Mood state; Craving; Cocaine use **59**, 33

Cocaine dependence; Major depression; Dual-diagnosis; Substance abuse comorbidity; Drug abuse **60**, 189

Cocaine; Drug abuse treatment; Outpatient treatment; Aftercare; Heroin; Contingency management; Housing; Employment **57**, 211

Cocaine; Drug self-administration; Propofol; Methohexital; Feeding; Primates; Abuse **57**, 51

Cocaine; HIV; Prevention initiatives **58**, 215

Cocaine; Pergolide; Alcohol; Clinical trial; Pharmacotherapy **60**, 161

Cocaine; Self-administration; Conditioned reinforcement; Extinction; Relapse **57**, 41

Cocaine; Self-help groups; Alcoholics anonymous; Treatment; Drug abuse **60**, 169

Cocaine; Substance abuse; Treatment; Homeless; Dual diagnosis **60**, 55

Cocaine use; Cue reactivity; Cocaine dependence; Mood state; Craving **59**, 33

Cocaine use; Drug treatment history; Treatment process; Treatment outcome; Social support; Environmental context **57**, 137

Cocaine; Withdrawal; Human; Outpatient; Drug dependence **59**, 277

Cognitive performance; Moderate drinking; Psychosocial models; Mental health; Alcohol consumption; Psychological benefits **60**, 221

Cognitive processes; Reinforcers; Sequence **59**, 51

Comorbidity; Age of onset; Substance use disorders; Personality disorders; Psychopathology **59**, 305

Comorbidity; HIV prevention; Drug abuse; AIDS; Antisocial personality; Depression **58**, 247

Compassionate use; Marijuana, medical uses; Legal aspects; Indications; Questionnaire **58**, 3

Compliance; Contingency management; Incentives; Vouchers; Medication management; Substance abuse treatment **58**, 9

Concordance; Urinalysis; Self-report; Validity; Methadone **59**, 43

Conditioned reinforcement; Cocaine; Self-administration; Extinction; Relapse **57**, 41

Conduct disorder; Substance use; Attention-deficit hyperactivity disorder; Major depressive disorder; Gender; Adolescents **59**, 131

Consequences of alcohol consumption; Russia; Alcohol consumption; Registered and unregistered alcohol consumption **58**, 133

Contingency contracting; Voucher-based reinforcement; Abstinence initiation; Cocaine abuse; Urinalysis; Methadone patients **58**, 205

Contingency-management; Cigarette smoking; Substance abuse; Relapse; Schedules of reinforcement; Treatment **58**, 103

Contingency management; Drug abuse treatment; Outpatient treatment; Aftercare; Heroin; Cocaine; Housing; Employment **57**, 211

Contingency management; Incentives; Vouchers; Medication management; Compliance; Substance abuse treatment **58**, 9

Contingency management; Treatment efficacy; Methadone maintenance; Meta-analysis **58**, 55

Controlled Substances Act; Tramadol HCl; Drug abuse; Drug dependence; Ultram®; Postmarketing surveillance **57**, 7

Convulsive status epilepticus; Benzodiazepine; Flunitrazepam; Lorazepam; Seizures; Side effects; Withdrawal **59**, 95

Cortical hemoglobin deoxygenation; Heroin; Methadone; Rush; Intravenous opioid treatment; Near infrared spectroscopy (NIRS); PROVE **57**, 23

Corticosterone; Ibogaine; MK-801; Dopamine; Prolactin; Addiction **59**, 143

Cost-benefit; Drug treatment costs; Treatment benefits; Crime costs; Cocaine addiction **57**, 167

Cost-benefit model; DATOS; Treatment process **57**, 81

Cotinine; Nicotine; Metabolism; Pharmacokinetics; Addiction; Tobacco; Pharmacodynamics **60**, 13

Counseling; Drug treatment; Treatment process; Self-help groups; Retention **57**, 99

Crack; African-American; Alcohol; HIV; Sexual risk **58**, 259

Crack cocaine; Cocaine; Cardiovascular response; Blood pressure; Heart rate; Toxicity **57**, 239

Crack; HIV; Injection drug user; Sex risk **58**, 219

Crack; IDUs; HIV; Women **58**, 227

Crack users; HIV **58**, 237

Craving; Cue reactivity; Cocaine dependence; Mood state; Cocaine use **59**, 33

Crime costs; Drug treatment costs; Treatment benefits; Cocaine addiction; Cost-benefit **57**, 167

Crime reduction; Heroin; Treatment outcome **58**, 165

Cross culture comparisons; Student drinking; Alcohol consumption *per capita* **60**, 315

Cue exposure; Alcohol; Dependent drinkers; Generalisation; Relapse prevention **57**, 29

Cue; Opiate dependence; Heroin; Neuroimaging **60**, 207

Cue reactivity; Cocaine dependence; Mood state; Craving; Cocaine use **59**, 33

Cytometry; Ethanol preference; Rats; Lymphocyte subsets; Circadian cycle **60**, 303

DATOS; Treatment process; Cost-benefit model **57**, 81

DATOS; Treatment process; Therapeutic engagements; Treatment retention; Motivation **57**, 113

Delay discounting; Delay discounting; Drug abuse; Heroin; Impulsivity; Needle sharing; Opioid; Self control; Risky injection **60**, 259

Delay discounting; Drug abuse; Heroin; Impulsivity; Needle sharing; Opioid; Self control; Delay discounting; Risky injection **60**, 259

Delta-9-tetrahydrocannabinol; Δ^9-THC; Cannabinoid; Tolerance; Time course **60**, 113

Dependence; Anabolic-androgenic steroids; Abuse; Women **60**, 91

Dependence; Cannabis; Follow-up; Australia **59**, 309

Dependence; Morphine; Tolerance; Macrophages; Phagocytosis; Immunology **58**, 159

Dependence symptoms; Alcohol dependence; Alcohol abuse; Diagnosis; Nosology **60**, 295

Dependent drinkers; Alcohol; Cue exposure; Generalisation; Relapse prevention **57**, 29

Depression; HIV prevention; Drug abuse; AIDS; Antisocial personality; Comorbidity **58**, 247

Detoxification; Dopamine receptor responsivity; Alcoholic patients **57**, 261

Detoxification; Opioids; Addiction severity index **58**, 85

DEXA; Alcoholism; Malnutrition; Social problems; Feeding habits; Liver disease **59**, 295

Diagnosis; Alcohol dependence; Alcohol abuse; Dependence symptoms; Nosology **60**, 295

Diagnosis; Reliability; Substance use disorders; Race **57**, 203

Diagnostic interviews; Adolescents; DSM-IV; SCID; Substance use disorders **59**, 173

1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM); β-carbolines; Harmaline; Harmine; Hallucinogens; Dimethyltryptamine (DMT); Serotonin receptors; Dopamine receptors; Benzodiazepine receptors; PI hydrolysis **60**, 121

Dimethyltryptamine (DMT); β-carbolines; Harmaline; Harmine; Hallucinogens; 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM); Serotonin receptors; Dopamine receptors; Benzodiazepine receptors; PI hydrolysis **60**, 121

Dopamine; Ibogaine; MK-801; Corticosterone; Prolactin; Addiction **59**, 143

Dopamine; Nicotine; Naloxone; Abstinence; Nucleus accumbens; Prefrontal cortex **58**, 93

Dopamine receptor responsivity; Alcoholic patients; Detoxification **57**, 261

Dopamine receptors; β-carbolines; Harmaline; Harmine; Hallucinogens; Dimethyltryptamine (DMT); 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM); Serotonin receptors; Benzodiazepine receptors; PI hydrolysis **60**, 121

DOP system; Alcohol consumption; CAGE; MAST; Farm workers; South Africa **59**, 199

Drinking; Risk factor; Sustained smoking **59**, 235

Dronabinol; Cannabinoid; Marijuana; Opioid; THC **59**, 251

Drug abuse; Cocaine dependence; Major depression; Dual-diagnosis; Substance abuse comorbidity **60**, 189

Drug abuse; Delay discounting; Heroin; Impulsivity; Needle sharing; Opioid; Self control; Delay discounting; Risky injection **60**, 259

Drug abuse; Drug dependence; Heroin; Opiate dependence; Self-report; Urine testing **58**, 111

Drug abuse; HIV/AIDS; Methadone maintenance treatment; Medicaid **60**, 77

Drug abuse; HIV prevention; AIDS; Antisocial personality; Depression; Comorbidity **58**, 247

Drug abuse; Risk taking; Antisocial behavior; Laboratory task **60**, 179

Drug abuse; Self-help groups; Alcoholics anonymous; Cocaine; Treatment **60**, 169

Drug abuse; Tramadol HCl; Drug dependence; Ultram®; Postmarketing surveillance; Controlled Substances Act **57**, 7

Drug Abuse Treatment Outcome Studies; Treatment engagement; Motivation; Program differences **57**, 127

Drug abuse treatment; Outpatient treatment; Aftercare; Heroin; Cocaine; Contingency management; Housing; Employment **57**, 211

Drug and alcohol abuse; Twin study; Genetics **57**, 69

Drug dependence; Cocaine; Withdrawal; Human; Outpatient **59**, 277

Drug dependence; Drug abuse; Heroin; Opiate dependence; Self-report; Urine testing **58**, 111

Drug dependence; Tramadol HCl; Drug abuse; Ultram®; Postmarketing surveillance; Controlled Substances Act **57**, 7

Drug history; Brain imaging; Cocaine; Intravenous; Safety **58**, 35

Drug interactions; Clozapine; Cocaine; Humans **59**, 153

Drug maintenance treatment; HIV; Injection drug users; Viral load; Buprenorphine **60**, 51

Drugs; Aggression; Relationships; Alcohol; Violence **58**, 43

Drug self-administration; Propofol; Methohexital; Cocaine; Feeding; Primates; Abuse **57**, 51

Drug treatment costs; Treatment benefits; Crime costs; Cocaine addiction; Cost-benefit **57**, 167

Drug treatment history; Treatment process; Treatment outcome; Social support; Environmental context; Cocaine use **57**, 137

Drug treatment; Treatment process; Counseling; Self-help groups; Retention **57**, 99

Drug use; Acculturation; Ethnic; Gender; Aggression **59**, 165

Drug use; Epidemiology; Panama; Alternating logistic regression; Clustering; Schools **60**, 251

Drug use; Epidemiology; Regression; Stimulants **59**, 89

Drug use frequency underreporting; Monte Carlo models; Hardcore drug use; Occasional drug use; Self-report; Methadone maintenance clients **57**, 193

Drug use history; Young adults; Treatment career; Self-efficacy; Reference group **57**, 151

Drug use; Natural recoveries; Autoremission; Service utilization **59**, 211

Drug use; Overdose; Methadone; Treatment; Suicide **58**, 117

DSM-IV; Adolescents; Diagnostic interviews; SCID; Substance use disorders **59**, 173

DSM-IV dependence; Severity; Assessment; Reliability; Validity; Outcome measures **59**, 63

DSM-IV; Smokers; Psychiatric diagnosis; Patch treatment; Mental disorder **60**, 267

Dual-diagnosis; Cocaine dependence; Major depression; Substance abuse comorbidity; Drug abuse **60**, 189

Dual diagnosis; Substance abuse; Cocaine; Treatment; Homeless **60**, 55

Early termination; Hostility; Retention; Gender differences; Buprenorphine; Heroin; Opioid dependence; Substance abuse treatment **58**, 27

Ecstasy; MDMA; Serotonin; Impulsivity; Paranoia; Psychosis; Psychobiology; Psychiatry; Neurotoxin **60**, 105

Employment; Drug abuse treatment; Outpatient treatment; Aftercare; Heroin; Cocaine; Contingency management; Housing **57**, 211

Employment; Washington State; Treatment **60**, 151

Endocrinology; Testosterone; HIV status; Injection drug use **60**, 311

Endogenous opioids; Marijuana smoking; Δ^9-Tetrahydrocannabinol; Antinociception; Analgesia; Naltrexone; Subjective effects; Performance; Heart rate; Humans **59**, 261

Environmental context; Drug treatment history; Treatment process; Treatment outcome; Social support; Cocaine use **57**, 137

Ephedra; Ephedrine; Norephedrine; Pseudoephedrine; Cathine; Phenylpropanolamines; Amphetamine; Khat; Ma huang; Optical isomers; Herbal dietary supplements; Thermogenic agents **57**, 1

Ephedrine; Norephedrine; Pseudoephedrine; Cathine; Phenylpropanolamines; Amphetamine; Khat; Ma huang; Optical isomers; Ephedra; Herbal dietary supplements; Thermogenic agents **57**, 1

Epidemiologic factors; Logistic models; Residential mobility; Socioeconomic factors; Space-time clustering **57**, 183

Epidemiology; AUDIT; Survey methods **60**, 97

Epidemiology; Drug use; Panama; Alternating logistic regression; Clustering; Schools **60**, 251

Epidemiology; Drug use; Regression; Stimulants **59**, 89

Erythrocytes; *N*-acetylcysteine; Methanol-induced injury; Liver; Serum **57**, 61

Ethanol; Abstinence; Associative learning; Event related potentials; Neurophysiology **58**, 125

Ethanol; Calcium sequestration; Cocaine; Hepatotoxicity; Lipid peroxidation **58**, 77

Ethanol preference; Rats; Lymphocyte subsets; Cytometry; Circadian cycle **60**, 303

Ethanol; Taste perception; Bitter; Sweet; Sour; Humans **60**, 199

Ethnic; Acculturation; Drug use; Gender; Aggression **59**, 165

Evaluation; Substance misuse; Alcohol; Treatment outcomes; Clinical audit **59**, 189

Event related potentials; Ethanol; Abstinence; Associative learning; Neurophysiology **58**, 125

Exclusion criteria; Project MATCH; Treatment matching; Generalizability **59**, 177

Extinction; Cocaine; Self-administration; Conditioned reinforcement; Relapse **57**, 41

Farm workers; Alcohol consumption; CAGE; MAST; DOP system; South Africa **59**, 199

Feeding; Drug self-administration; Propofol; Methohexital; Cocaine; Primates; Abuse **57**, 51

Feeding habits; Alcoholism; Malnutrition; Social problems; Liver disease; DEXA **59**, 295

Flashbacks; Methamphetamine psychosis; Stressful experiences; Norepinephrine; 3-methoxytyramine **58**, 67

Flunitrazepam; Benzodiazepine; Convulsive status epilepticus; Lorazepam; Seizures; Side effects; Withdrawal **59**, 95

Follow-up; Cannabis; Dependence; Australia **59**, 309

Frequent drinking; Frequent smoking; Risk factors; Adolescent drug use; Substance use careers **60**, 319

Frequent smoking; Frequent drinking; Risk factors; Adolescent drug use; Substance use careers **60**, 319

Gender; Acculturation; Drug use; Ethnic; Aggression **59**, 165

Gender; Conduct disorder; Substance use; Attention-deficit hyperactivity disorder; Major depressive disorder; Adolescents **59**, 131

Gender differences; Hostility; Retention; Early termination; Buprenorphine; Heroin; Opioid dependence; Substance abuse treatment **58**, 27

Generalisation; Alcohol; Cue exposure; Dependent drinkers; Relapse prevention **57**, 29

Generalizability; Project MATCH; Treatment matching; Exclusion criteria **59**, 177

Genetics; Drug and alcohol abuse; Twin study **57**, 69

Genotype–environment interaction; Substance abuse; Behavioral phenotype **59**, 101

Greece; High-school students; Substance use; Trends **58**, 181

Growth hormone; Alcohol withdrawal; Clonidine; Noradrenergic activity **57**, 255

Hallucinogens; β-carbolines; Harmaline; Harmine; Dimethyltryptamine (DMT); 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM); Serotonin receptors; Dopamine receptors; Benzodiazepine receptors; PI hydrolysis **60**, 121

Hardcore drug use; Drug use frequency underreporting; Monte Carlo models; Occasional drug use; Self-report; Methadone maintenance clients **57**, 193

Harmaline; β-carbolines; Harmine; Hallucinogens; Dimethyltryptamine (DMT); 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM); Serotonin receptors; Dopamine receptors; Benzodiazepine receptors; PI hydrolysis **60**, 121

Harmine; β-carbolines; Harmaline; Hallucinogens; Dimethyltryptamine (DMT); 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM); Serotonin receptors; Dopamine receptors; Benzodiazepine receptors; PI hydrolysis **60**, 121

Harms; Heroin; Amphetamines; Injecting drug use **58**, 189

Heart rate; Cocaine; Crack cocaine; Cardiovascular response; Blood pressure; Toxicity **57**, 239

Heart rate; Marijuana smoking; Δ^9-Tetrahydrocannabinol; Antinociception; Analgesia; Endogenous opioids; Naltrexone; Subjective effects; Performance; Humans **59**, 261

Hepatotoxicity; Calcium sequestration; Cocaine; Ethanol; Lipid peroxidation **58**, 77

Herbal dietary supplements; Ephedrine; Norephedrine; Pseudoephedrine; Cathine; Phenylpropanolamines; Amphetamine; Khat; Ma huang; Optical isomers; Ephedra; Thermogenic agents **57**, 1

Heroin; Amphetamines; Harms; Injecting drug use **58**, 189

Heroin; Buprenorphine; Methadone maintenance; Addiction **60**, 39

Heroin; Crime reduction; Treatment outcome **58**, 165

Heroin; Delay discounting; Drug abuse; Impulsivity; Needle sharing; Opioid; Self control; Delay discounting; Risky injection **60**, 259

Heroin; Drug abuse; Drug dependence; Opiate dependence; Self-report; Urine testing **58**, 111

Heroin; Drug abuse treatment; Outpatient treatment; Aftercare; Cocaine; Contingency management; Housing; Employment **57**, 211

Heroin; Hostility; Retention; Early termination; Gender differences; Buprenorphine; Opioid dependence; Substance abuse treatment **58**, 27

Heroin; Methadone; Cortical hemoglobin deoxygenation; Rush; Intravenous opioid treatment; Near infrared spectroscopy (NIRS); PROVE **57**, 23

Heroin; Opiate dependence; Cue; Neuroimaging **60**, 207

Heroin-related deaths; Morphine; Poldrug use **60**, 141

Heroin treatment; Alternate-day dosing; Buprenorphine; Buprenorphine–naloxone; Human; Methadone treatment **58**, 143

Heroin treatment; Methadone maintenance; Treatment retention **58**, 173

High-school students; Greece; Substance use; Trends **58**, 181

HIV; African-American; Alcohol; Crack; Sexual risk **58**, 259

HIV/AIDS; Drug abuse; Methadone maintenance treatment; Medicaid **60**, 77

HIV/AIDS prevention; Treatment; Methadone maintenance; Risk behavior **59**, 17

HIV; Brazil; Cocaine **58**, 267

HIV; Cocaine; Prevention initiatives **58**, 215

HIV; Crack; Injection drug user; Sex risk **58**, 219

HIV; Crack users **58**, 237

HIV; IDUs; Crack; Women **58**, 227

HIV; Injection drug users; Drug maintenance treatment; Viral load; Buprenorphine **60**, 51

HIV prevention; Drug abuse; AIDS; Antisocial personality; Depression; Comorbidity **58**, 247

HIV-1 RNA load; Injecting drug user; Blood; Needle/syringe; Paraphernalia; Shooting gallery; AIDS **58**, 153

HIV status; Endocrinology; Testosterone; Injection drug use **60**, 311

Homeless; Substance abuse; Cocaine; Treatment; Dual diagnosis **60**, 55

Hostility; Retention; Early termination; Gender differences; Buprenorphine; Heroin; Opioid dependence; Substance abuse treatment **58**, 27

Housing; Drug abuse treatment; Outpatient treatment; Aftercare; Heroin; Cocaine; Contingency management; Employment **57**, 211

Human; Alternate-day dosing; Buprenorphine; Buprenorphine–naloxone; Heroin treatment; Methadone treatment **58**, 143

Human; Cocaine; Withdrawal; Outpatient; Drug dependence **59**, 277

Humans; Clozapine; Cocaine; Drug interactions **59**, 153

Humans; Ethanol; Taste perception; Bitter; Sweet; Sour **60**, 199

Humans; Marijuana smoking; Δ^9-Tetrahydrocannabinol; Antinociception; Analgesia; Endogenous opioids; Naltrexone; Subjective effects; Performance; Heart rate **59**, 261

Ibogaine; MK-801; Dopamine; Corticosterone; Prolactin; Addiction **59**, 143

IDUs; Crack; HIV; Women **58**, 227

Illegal drugs; Alcohol; Road traffic accidents; Spain **57**, 177

Illicit drugs; Impaired driving; Impairment beliefs; Accident involvement **58**, 197

Illicit drugs; Medical students; Alcohol; Stress; Personality **59**, 125

Immunology; Morphine; Tolerance; Dependence; Macrophages; Phagocytosis **58**, 159

Impaired driving; Illicit drugs; Impairment beliefs; Accident involvement **58**, 197

Impairment beliefs; Illicit drugs; Impaired driving; Accident involvement **58**, 197

Impulsivity; Delay discounting; Drug abuse; Heroin; Needle sharing; Opioid; Self control; Delay discounting; Risky injection **60**, 259

Impulsivity; MDMA; Ecstasy; Serotonin; Paranoia; Psychosis; Psychobiology; Psychiatry; Neurotoxin **60**, 105

Incentives; Contingency management; Vouchers; Medication management; Compliance; Substance abuse treatment **58**, 9

Indications; Marijuana, medical uses; Compassionate use; Legal aspects; Questionnaire **58**, 3

Injecting drug use; Heroin; Amphetamines; Harms **58**, 189

Injecting drug user; Blood; Needle/syringe; Paraphernalia; Shooting gallery; HIV-1 RNA load; AIDS **58**, 153

Injection drug use; Endocrinology; Testosterone; HIV status **60**, 311

Injection drug user; HIV; Crack; Sex risk **58**, 219

Injection drug users; HIV; Drug maintenance treatment; Viral load; Buprenorphine **60**, 51

Intravenous; Brain imaging; Cocaine; Drug history; Safety **58**, 35

Intravenous opioid treatment; Heroin; Methadone; Cortical hemoglobin deoxygenation; Rush; Near infrared spectroscopy (NIRS); PROVE **57**, 23

Khat; Ephedrine; Norephedrine; Pseudoephedrine; Cathine; Phenylpropanolamines; Amphetamine; Ma huang; Optical isomers; Ephedra; Herbal dietary supplements; Thermogenic agents **57**, 1

Laboratory task; Risk taking; Antisocial behavior; Drug abuse **60**, 179

Legal aspects; Marijuana, medical uses; Compassionate use; Indications; Questionnaire **58**, 3

Lipid peroxidation; Calcium sequestration; Cocaine; Ethanol; Hepatotoxicity **58**, 77

Liver disease; Alcoholism; Malnutrition; Social problems; Feeding habits; DEXA **59**, 295

Liver; *N*-acetylcysteine; Methanol-induced injury; Erythrocytes; Serum **57**, 61

Lofexidine; Naltrexone; Opiate detoxification **59**, 183

Logistic models; Epidemiologic factors; Residential mobility; Socioeconomic factors; Space-time clustering **57**, 183

Lorazepam; Benzodiazepine; Convulsive status epilepticus; Flunitrazepam; Seizures; Side effects; Withdrawal **59**, 95

Lymphocyte subsets; Ethanol preference; Rats; Cytometry; Circadian cycle **60**, 303

Macrophages; Morphine; Tolerance; Dependence; Phagocytosis; Immunology **58**, 159

Ma huang; Ephedrine; Norephedrine; Pseudoephedrine; Cathine; Phenylpropanolamines; Amphetamine; Khat; Optical isomers; Ephedra; Herbal dietary supplements; Thermogenic agents **57**, 1

Major depression; Cocaine dependence; Dual-diagnosis; Substance abuse comorbidity; Drug abuse **60**, 189

Major depressive disorder; Conduct disorder; Substance use; Attention-deficit hyperactivity disorder; Gender; Adolescents **59**, 131

Malnutrition; Alcoholism; Social problems; Feeding habits; Liver disease; DEXA **59**, 295

Marijuana; Cannabinoid; Dronabinol; Opioid; THC **59**, 251

Marijuana, medical uses; Compassionate use; Legal aspects; Indications; Questionnaire **58**, 3

Marijuana smoking; Δ^9-Tetrahydrocannabinol; Antinociception; Analgesia; Endogenous opioids; Naltrexone; Subjective effects; Performance; Heart rate; Humans **59**, 261

MAST; Alcohol consumption; CAGE; DOP system; Farm workers; South Africa **59**, 199

MDMA; Ecstasy; Serotonin; Impulsivity; Paranoia; Psychosis; Psychobiology; Psychiatry; Neurotoxin **60**, 105

Medicaid; HIV/AIDS; Drug abuse; Methadone maintenance treatment **60**, 77

Medical students; Alcohol; Illicit drugs; Stress; Personality **59**, 125

Medication management; Contingency management; Incentives; Vouchers; Compliance; Substance abuse treatment **58**, 9

Mental disorder; Smokers; Psychiatric diagnosis; Patch treatment; DSM-IV **60**, 267

Mental health; Moderate drinking; Psychosocial models; Cognitive performance; Alcohol consumption; Psychological benefits **60**, 221

Meta-analysis; Contingency management; Treatment efficacy; Methadone maintenance **58**, 55

Metabolism; Nicotine; Cotinine; Pharmacokinetics; Addiction; Tobacco; Pharmacodynamics **60**, 13

Methadone; Drug use; Overdose; Treatment; Suicide **58**, 117

Methadone; Heroin; Cortical hemoglobin deoxygenation; Rush; Intravenous opioid treatment; Near infrared spectroscopy (NIRS); PROVE **57**, 23

Methadone maintenance; Buprenorphine; Heroin; Addiction **60**, 39

Methadone maintenance clients; Drug use frequency underreporting; Monte Carlo models; Hardcore drug use; Occasional drug use; Self-report **57**, 193

Methadone maintenance; Contingency management; Treatment efficacy; Meta-analysis **58**, 55

Methadone maintenance; HIV/AIDS prevention; Treatment; Risk behavior **59**, 17

Methadone maintenance; Parent training skills; Parent–child relationship **60**, 1

Methadone maintenance treatment; HIV/AIDS; Drug abuse; Medicaid **60**, 77

Methadone maintenance; Treatment retention; Heroin treatment **58**, 173

Methadone; Opioid; Overdose **57**, 247

Methadone patients; Voucher-based reinforcement; Abstinence initiation; Cocaine abuse; Urinalysis; Contingency contracting **58**, 205

Methadone treatment; Alternate-day dosing; Buprenorphine; Buprenorphine–naloxone; Heroin treatment; Human **58**, 143

Methadone; Treatment; Outcome; Response profiles **60**, 275

Methadone; Urinalysis; Self-report; Concordance; Validity **59**, 43

Methamphetamine psychosis; Flashbacks; Stressful experiences; Norepinephrine; 3-methoxytyramine **58**, 67

Methanol-induced injury; *N*-acetylcysteine; Liver; Erythrocytes; Serum **57**, 61

Methohexital; Drug self-administration; Propofol; Cocaine; Feeding; Primates; Abuse **57**, 51

3-methoxytyramine; Methamphetamine psychosis; Flashbacks; Stressful experiences; Norepinephrine **58**, 67

MK-801; Ibogaine; Dopamine; Corticosterone; Prolactin; Addiction **59**, 143

Moderate drinking; Psychosocial models; Mental health; Cognitive performance; Alcohol consumption; Psychological benefits **60**, 221

Monte Carlo models; Drug use frequency underreporting; Hardcore drug use; Occasional drug use; Self-report; Methadone maintenance clients **57**, 193

Mood state; Cue reactivity; Cocaine dependence; Craving; Cocaine use **59**, 33

Morphine; Heroin-related deaths; Poldrug use **60**, 141

Morphine; Nalmefene; Subjective effects; Blockade; Pharmacology **60**, 29

Morphine; Tolerance; Dependence; Macrophages; Phagocytosis; Immunology **58**, 159

Motivation; Treatment engagement; Program differences; Drug Abuse Treatment Outcome Studies **57**, 127

Motivation; Treatment process; Therapeutic engagements; Treatment retention; DATOS **57**, 113

Multiple logistic regression analyses; Residential treatment; 1 year outcomes **57**, 89

***N*-acetylcysteine**; Methanol-induced injury; Liver; Erythrocytes; Serum **57**, 61

Nalmefene; Morphine; Subjective effects; Blockade; Pharmacology **60**, 29

Naloxone; Dopamine; Nicotine; Abstinence; Nucleus accumbens; Prefrontal cortex **58**, 93

Naltrexone; Lofexidine; Opiate detoxification **59**, 183

Naltrexone; Marijuana smoking; Δ^9-Tetrahydrocannabinol; Antinociception; Analgesia; Endogenous opioids; Subjective effects; Performance; Heart rate; Humans **59**, 261

Naltrexone; Opiate withdrawal; Trazodone; Clonidine **59**, 287

Natural recoveries; Autoremission; Drug use; Service utilization **59**, 211

Near infrared spectroscopy (NIRS); Heroin; Methadone; Cortical hemoglobin deoxygenation; Rush; Intravenous opioid treatment; PROVE **57**, 23

Needle sharing; Delay discounting; Drug abuse; Heroin; Impulsivity; Opioid; Self control; Delay discounting; Risky injection **60**, 259

Needle/syringe; Injecting drug user; Blood; Paraphernalia; Shooting gallery; HIV-1 RNA load; AIDS **58**, 153

Neuroimaging; Opiate dependence; Heroin; Cue **60**, 207

Neurophysiology; Ethanol; Abstinence; Associative learning; Event related potentials **58**, 125

Neurotoxin; MDMA; Ecstasy; Serotonin; Impulsivity; Paranoia; Psychosis; Psychobiology; Psychiatry **60**, 105

Nicotine; Cotinine; Metabolism; Pharmacokinetics; Addiction; Tobacco; Pharmacodynamics **60**, 13

Nicotine; Dopamine; Naloxone; Abstinence; Nucleus accumbens; Prefrontal cortex **58**, 93

NMDA receptor antagonists; Opiates; Psychostimulants; Alcohol; Pharmacotherapy **59**, 1

Noradrenergic activity; Alcohol withdrawal; Clonidine; Growth hormone **57**, 255

Norephedrine; Ephedrine; Pseudoephedrine; Cathine; Phenylpropanolamines; Amphetamine; Khat; Ma huang; Optical isomers; Ephedra; Herbal dietary supplements; Thermogenic agents **57**, 1

Norepinephrine; Methamphetamine psychosis; Flashbacks; Stressful experiences; 3-methoxytyramine **58**, 67

Nosology; Alcohol abuse; Alcohol dependence; Subtypes of alcohol dependence; Subtypes of alcohol abuse **60**, 287

Nosology; Alcohol dependence; Alcohol abuse; Dependence symptoms; Diagnosis **60**, 295

Nucleus accumbens; Dopamine; Nicotine; Naloxone; Abstinence; Prefrontal cortex **58**, 93

Occasional drug use; Drug use frequency underreporting; Monte Carlo models; Hardcore drug use; Self-report; Methadone maintenance clients **57**, 193

Opiate dependence; Drug abuse; Drug dependence; Heroin; Self-report; Urine testing **58**, 111

Opiate dependence; Heroin; Cue; Neuroimaging **60**, 207

Opiate detoxification; Lofexidine; Naltrexone **59**, 183

Opiates; NMDA receptor antagonists; Psychostimulants; Alcohol; Pharmacotherapy **59**, 1

Opiate withdrawal; Naltrexone; Trazodone; Clonidine **59**, 287

Opioid; Cannabinoid; Dronabinol; Marijuana; THC **59**, 251

Opioid; Delay discounting; Drug abuse; Heroin; Impulsivity; Needle sharing; Self control; Delay discounting; Risky injection **60**, 259

Opioid dependence; Buprenorphine; Treatment; Thrice-weekly dosing **59**, 223

Opioid dependence; Hostility; Retention; Early termination; Gender differences; Buprenorphine; Heroin; Substance abuse treatment **58**, 27

Opioid; Methadone; Overdose **57**, 247

Opioids; Detoxification; Addiction severity index **58**, 85

Optical isomers; Ephedrine; Norephedrine; Pseudoephedrine; Cathine; Phenylpropanolamines; Amphetamine; Khat; Ma huang; Ephedra; Herbal dietary supplements; Thermogenic agents **57**, 1

Outcome measures; DSM-IV dependence; Severity; Assessment; Reliability; Validity **59**, 63

Outcome; Methadone; Treatment; Response profiles **60**, 275

Outpatient; Cocaine; Withdrawal; Human; Drug dependence **59**, 277

Outpatient treatment; Drug abuse treatment; Aftercare; Heroin; Cocaine; Contingency management; Housing; Employment **57**, 211

Overdose; Drug use; Methadone; Treatment; Suicide **58**, 117

Overdose; Opioid; Methadone **57**, 247

Panama; Epidemiology; Drug use; Alternating logistic regression; Clustering; Schools **60**, 251

Paranoia; MDMA; Ecstasy; Serotonin; Impulsivity; Psychosis; Psychobiology; Psychiatry; Neurotoxin **60**, 105

Paraphernalia; Injecting drug user; Blood; Needle/syringe; Shooting gallery; HIV-1 RNA load; AIDS **58**, 153

Parent–child relationship; Methadone maintenance; Parent training skills **60**, 1

Parent training skills; Methadone maintenance; Parent–child relationship **60**, 1

Patch treatment; Smokers; Psychiatric diagnosis; Mental disorder; DSM-IV **60**, 267

Performance; Marijuana smoking; Δ^9-Tetrahydrocannabinol; Antinociception; Analgesia; Endogenous opioids; Naltrexone; Subjective effects; Heart rate; Humans **59**, 261

Pergolide; Cocaine; Alcohol; Clinical trial; Pharmacotherapy **60**, 161

Personality disorders; Age of onset; Substance use disorders; Psychopathology; Comorbidity **59**, 305

Personality; Medical students; Alcohol; Illicit drugs; Stress **59**, 125

Phagocytosis; Morphine; Tolerance; Dependence; Macrophages; Immunology **58**, 159

Pharmacodynamics; Nicotine; Cotinine; Metabolism; Pharmacokinetics; Addiction; Tobacco **60**, 13

Pharmacokinetics; Nicotine; Cotinine; Metabolism; Addiction; Tobacco; Pharmacodynamics **60**, 13

Pharmacology; Nalmefene; Morphine; Subjective effects; Blockade **60**, 29

Pharmacotherapy; Cocaine; Pergolide; Alcohol; Clinical trial **60**, 161

Pharmacotherapy; NMDA receptor antagonists; Opiates; Psychostimulants; Alcohol **59**, 1

Phenylpropanolamines; Ephedrine; Norephedrine; Pseudoephedrine; Cathine; Amphetamine; Khat; Ma huang; Optical isomers; Ephedra; Herbal dietary supplements; Thermogenic agents **57**, 1

PI hydrolysis; β-carbolines; Harmaline; Harmine; Hallucinogens; Dimethyltryptamine (DMT); 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM); Serotonin receptors; Dopamine receptors; Benzodiazepine receptors **60**, 121

Poldrug use; Heroin-related deaths; Morphine **60**, 141

Postmarketing surveillance; Tramadol HCl; Drug abuse; Drug dependence; Ultram®; Controlled Substances Act **57**, 7

Predictive validity; Substance Dependence Severity Scale; Assessment **59**, 77

Prefrontal cortex; Dopamine; Nicotine; Naloxone; Abstinence; Nucleus accumbens **58**, 93

Prevention initiatives; HIV; Cocaine **58**, 215

Primates; Drug self-administration; Propofol; Methohexital; Cocaine; Feeding; Abuse **57**, 51

Program differences; Treatment engagement; Motivation; Drug Abuse Treatment Outcome Studies **57**, 127

Project MATCH; Treatment matching; Generalizability; Exclusion criteria **59**, 177

Prolactin; Ibogaine; MK-801; Dopamine; Corticosterone; Addiction **59**, 143

Propofol; Drug self-administration; Methohexital; Cocaine; Feeding; Primates; Abuse **57**, 51

PROVE; Heroin; Methadone; Cortical hemoglobin deoxygenation; Rush; Intravenous opioid treatment; Near infrared spectroscopy (NIRS) **57**, 23

Pseudoephedrine; Ephedrine; Norephedrine; Cathine; Phenylpropanolamines; Amphetamine; Khat; Ma huang; Optical isomers; Ephedra; Herbal dietary supplements; Thermogenic agents **57**, 1

Psychiatric diagnosis; Smokers; Patch treatment; Mental disorder; DSM-IV **60**, 267

Psychiatry; MDMA; Ecstasy; Serotonin; Impulsivity; Paranoia; Psychosis; Psychobiology; Neurotoxin **60**, 105

Psychobiology; MDMA; Ecstasy; Serotonin; Impulsivity; Paranoia; Psychosis; Psychiatry; Neurotoxin **60**, 105

Psychological benefits; Moderate drinking; Psychosocial models; Mental health; Cognitive performance; Alcohol consumption **60**, 221

Psychopathology; Age of onset; Substance use disorders; Personality disorders; Comorbidity **59**, 305

Psychosis; MDMA; Ecstasy; Serotonin; Impulsivity; Paranoia; Psychobiology; Psychiatry; Neurotoxin **60**, 105

Psychosocial models; Moderate drinking; Mental health; Cognitive performance; Alcohol consumption; Psychological benefits **60**, 221

Psychostimulants; NMDA receptor antagonists; Opiates; Alcohol; Pharmacotherapy **59**, 1

Questionnaire; Marijuana, medical uses; Compassionate use; Legal aspects; Indications **58**, 3

Race; Reliability; Substance use disorders; Diagnosis **57**, 203

Radioligand binding; Cannabinoid; Cannabinoid receptors; Affinity; Cannabimimetic indoles; Aminoalkylindoles **60**, 133

Rats; Ethanol preference; Lymphocyte subsets; Cytometry; Circadian cycle **60**, 303

Reference group; Young adults; Drug use history; Treatment career; Self-efficacy **57**, 151

Registered and unregistered alcohol consumption; Russia; Alcohol consumption; Consequences of alcohol consumption **58**, 133

Regression; Epidemiology; Drug use; Stimulants **59**, 89

Reinforcers; Cognitive processes; Sequence **59**, 51

Relapse; Cigarette smoking; Contingency-management; Substance abuse; Schedules of reinforcement; Treatment **58**, 103

Relapse; Cocaine; Self-administration; Conditioned reinforcement; Extinction **57**, 41

Relapse prevention; Alcohol; Cue exposure; Dependent drinkers; Generalisation **57**, 29

Relationships; Aggression; Alcohol; Drugs; Violence **58**, 43

Reliability; DSM-IV dependence; Severity; Assessment; Validity; Outcome measures **59**, 63

Reliability; Substance use disorders; Race; Diagnosis **57**, 203

Reliability; Substance use reports; Agreement rates; Adolescents; Surveys **60**, 19

Residential mobility; Epidemiologic factors; Logistic models; Socioeconomic factors; Space-time clustering **57**, 183

Residential treatment; 1 year outcomes; Multiple logistic regression analyses **57**, 89

Response profiles; Methadone; Treatment; Outcome **60**, 275

Retention; Drug treatment; Treatment process; Counseling; Self-help groups **57**, 99

Retention; Hostility; Early termination; Gender differences; Buprenorphine; Heroin; Opioid dependence; Substance abuse treatment **58**, 27

Risk behavior; HIV/AIDS prevention; Treatment; Methadone maintenance **59**, 17

Risk factor; Drinking; Sustained smoking **59**, 235

Risk factors; Frequent smoking; Frequent drinking; Adolescent drug use; Substance use careers **60**, 319

Risk taking; Antisocial behavior; Drug abuse; Laboratory task **60**, 179

Risky injection; Delay discounting; Drug abuse; Heroin; Impulsivity; Needle sharing; Opioid; Self control; Delay discounting **60**, 259

Road traffic accidents; Illegal drugs; Alcohol; Spain **57**, 177

Rush; Heroin; Methadone; Cortical hemoglobin deoxygenation; Intravenous opioid treatment; Near infrared spectroscopy (NIRS); PROVE **57**, 23

Russia; Alcohol consumption; Registered and unregistered alcohol consumption; Consequences of alcohol consumption **58**, 133

Safety; Brain imaging; Cocaine; Drug history; Intravenous **58**, 35

Schedules of reinforcement; Cigarette smoking; Contingency-management; Substance abuse; Relapse; Treatment **58**, 103

Schools; Epidemiology; Drug use; Panama; Alternating logistic regression; Clustering **60**, 251

SCID; Adolescents; Diagnostic interviews; DSM-IV; Substance use disorders **59**, 173

Seizures; Benzodiazepine; Convulsive status epilepticus; Flunitrazepam; Lorazepam; Side effects; Withdrawal **59**, 95

Self-administration; Adrenergic receptors; Carvedilol; Cocaine; Cardiovascular effects **60**, 69

Self-administration; Cocaine; Conditioned reinforcement; Extinction; Relapse **57**, 41

Self control; Delay discounting; Drug abuse; Heroin; Impulsivity; Needle sharing; Opioid; Delay discounting; Risky injection **60**, 259

Self-efficacy; Young adults; Drug use history; Treatment career; Reference group **57**, 151

Self-help groups; Alcoholics anonymous; Cocaine; Treatment; Drug abuse **60**, 169

Self-help groups; Drug treatment; Treatment process; Counseling; Retention **57**, 99

Self-report; Drug abuse; Drug dependence; Heroin; Opiate dependence; Urine testing **58**, 111

Self-report; Drug use frequency underreporting; Monte Carlo models; Hardcore drug use; Occasional drug use; Methadone maintenance clients **57**, 193

Self-report; Urinalysis; Concordance; Validity; Methadone **59**, 43

Sequence; Cognitive processes; Reinforcers **59**, 51

Serotonin; MDMA; Ecstasy; Impulsivity; Paranoia; Psychosis; Psychobiology; Psychiatry; Neurotoxin **60**, 105

Serotonin receptors; β-carbolines; Harmaline; Harmine; Hallucinogens; Dimethyltryptamine (DMT); 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM); Dopamine receptors; Benzodiazepine receptors; PI hydrolysis **60**, 121

Serum; *N*-acetylcysteine; Methanol-induced injury; Liver; Erythrocytes **57**, 61

Service utilization; Natural recoveries; Autoremission; Drug use **59**, 211

Severity; DSM-IV dependence; Assessment; Reliability; Validity; Outcome measures **59**, 63

Sex risk; HIV; Crack; Injection drug user **58**, 219

Sexual risk; African-American; Alcohol; Crack; HIV **58**, 259

Shooting gallery; Injecting drug user; Blood; Needle/syringe; Paraphernalia; HIV-1 RNA load; AIDS **58**, 153

Side effects; Benzodiazepine; Convulsive status epilepticus; Flunitrazepam; Lorazepam; Seizures; Withdrawal **59**, 95

Smokers; Psychiatric diagnosis; Patch treatment; Mental disorder; DSM-IV **60**, 267

Social problems; Alcoholism; Malnutrition; Feeding habits; Liver disease; DEXA **59**, 295

Social support; Drug treatment history; Treatment process; Treatment outcome; Environmental context; Cocaine use **57**, 137

Socioeconomic factors; Epidemiologic factors; Logistic models; Residential mobility; Space-time clustering **57**, 183

Sour; Ethanol; Taste perception; Bitter; Sweet; Humans **60**, 199

South Africa; Alcohol consumption; CAGE; MAST; DOP system; Farm workers **59**, 199

Space-time clustering; Epidemiologic factors; Logistic models; Residential mobility; Socioeconomic factors **57**, 183

Spain; Illegal drugs; Alcohol; Road traffic accidents **57**, 177

Stimulants; Epidemiology; Drug use; Regression **59**, 89

Stressful experiences; Methamphetamine psychosis; Flashbacks; Norepinephrine; 3-methoxytyramine **58**, 67

Stress; Medical students; Alcohol; Illicit drugs; Personality **59**, 125

Student drinking; Cross culture comparisons; Alcohol consumption *per capita* **60**, 315

Subjective effects; Marijuana smoking; Δ^9-Tetrahydrocannabinol; Antinociception; Analgesia; Endogenous opioids; Naltrexone; Performance; Heart rate; Humans **59**, 261

Subjective effects; Nalmefene; Morphine; Blockade; Pharmacology **60**, 29

Substance abuse; Cigarette smoking; Contingency-management; Relapse; Schedules of reinforcement; Treatment **58**, 103

Substance abuse; Cocaine; Treatment; Homeless; Dual diagnosis **60**, 55

Substance abuse comorbidity; Cocaine dependence; Major depression; Dual-diagnosis; Drug abuse **60**, 189

Substance abuse; Genotype–environment interaction; Behavioral phenotype **59**, 101

Substance abuse treatment; Contingency management; Incentives; Vouchers; Medication management; Compliance **58**, 9

Substance abuse treatment; Hostility; Retention; Early termination; Gender differences; Buprenorphine; Heroin; Opioid dependence **58**, 27

Substance Dependence Severity Scale; Assessment; Predictive validity **59**, 77

Substance misuse; Alcohol; Treatment outcomes; Evaluation; Clinical audit **59**, 189

Substance use careers; Frequent smoking; Frequent drinking; Risk factors; Adolescent drug use **60**, 319

Substance use; Conduct disorder; Attention-deficit hyperactivity disorder; Major depressive disorder; Gender; Adolescents **59**, 131

Substance use disorders; Adolescents; Diagnostic interviews; DSM-IV; SCID **59**, 173

Substance use disorders; Age of onset; Personality disorders; Psychopathology; Comorbidity **59**, 305

Substance use disorders; Reliability; Race; Diagnosis **57**, 203

Substance use; Greece; High-school students; Trends **58**, 181

Substance use reports; Agreement rates; Reliability; Adolescents; Surveys **60**, 19

Subtypes of alcohol abuse; Alcohol abuse; Alcohol dependence; Subtypes of alcohol dependence; Nosology **60**, 287

Subtypes of alcohol dependence; Alcohol abuse; Alcohol dependence; Subtypes of alcohol abuse; Nosology **60**, 287

Suicide; Drug use; Overdose; Methadone; Treatment **58**, 117

Survey methods; AUDIT; Epidemiology **60**, 97

Surveys; Substance use reports; Agreement rates; Reliability; Adolescents **60**, 19

Sustained smoking; Drinking; Risk factor **59**, 235

Sweet; Ethanol; Taste perception; Bitter; Sour; Humans **60**, 199

Taste perception; Ethanol; Bitter; Sweet; Sour; Humans **60**, 199

Testosterone; Endocrinology; HIV status; Injection drug use **60**, 311

Δ^9-Tetrahydrocannabinol; Marijuana smoking; Antinociception; Analgesia; Endogenous opioids; Naltrexone; Subjective effects; Performance; Heart rate; Humans **59**, 261

THC; Cannabinoid; Dronabinol; Marijuana; Opioid **59**, 251

Δ^9-THC; Delta-9-tetrahydrocannabinol; Cannabinoid; Tolerance; Time course **60**, 113

Therapeutic engagements; Treatment process; Treatment retention; Motivation; DATOS **57**, 113

Thermogenic agents; Ephedrine; Norephedrine; Pseudoephedrine; Cathine; Phenylpropanolamines; Amphetamine; Khat; Ma huang; Optical isomers; Ephedra; Herbal dietary supplements **57**, 1

Thrice-weekly dosing; Buprenorphine; Opioid dependence; Treatment **59**, 223

Time course; Delta-9-tetrahydrocannabinol; Δ^9-THC; Cannabinoid; Tolerance **60**, 113

Tobacco; Nicotine; Cotinine; Metabolism; Pharmacokinetics; Addiction; Pharmacodynamics **60**, 13

Tolerance; Delta-9-tetrahydrocannabinol; Δ^9-THC; Cannabinoid; Time course **60**, 113

Tolerance; Morphine; Dependence; Macrophages; Phagocytosis; Immunology **58**, 159

Toxicity; Cocaine; Crack cocaine; Cardiovascular response; Blood pressure; Heart rate **57**, 239

Tramadol HCl; Drug abuse; Drug dependence; Ultram®; Postmarketing surveillance; Controlled Substances Act **57**, 7

Trazodone; Opiate withdrawal; Naltrexone; Clonidine **59**, 287

Treatment benefits; Drug treatment costs; Crime costs; Cocaine addiction; Cost-benefit **57**, 167

Treatment; Buprenorphine; Opioid dependence; Thrice-weekly dosing **59**, 223

Treatment career; Young adults; Drug use history; Self-efficacy; Reference group **57**, 151

Treatment; Cigarette smoking; Contingency-management; Substance abuse; Relapse; Schedules of reinforcement **58**, 103

Treatment; Drug use; Overdose; Methadone; Suicide **58**, 117

Treatment efficacy; Contingency management; Methadone maintenance; Meta-analysis **58**, 55

Treatment engagement; Motivation; Program differences; Drug Abuse Treatment Outcome Studies **57**, 127

Treatment; HIV/AIDS prevention; Methadone maintenance; Risk behavior **59**, 17

Treatment matching; Project MATCH; Generalizability; Exclusion criteria **59**, 177

Treatment; Methadone; Outcome; Response profiles **60**, 275

Treatment outcome; Cocaine dependence; Baseline predictors **59**, 215

Treatment outcome; Crime reduction; Heroin **58**, 165

Treatment outcome; Drug treatment history; Treatment process; Social support; Environmental context; Cocaine use **57**, 137

Treatment outcomes; Substance misuse; Alcohol; Evaluation; Clinical audit **59**, 189

Treatment process; DATOS; Cost-benefit model **57**, 81

Treatment process; Drug treatment; Counseling; Self-help groups; Retention **57**, 99

Treatment process; Drug treatment history; Treatment outcome; Social support; Environmental context; Cocaine use **57**, 137

Treatment process; Therapeutic engagements; Treatment retention; Motivation; DATOS **57**, 113

Treatment retention; Methadone maintenance; Heroin treatment **58**, 173

Treatment retention; Treatment process; Therapeutic engagements; Motivation; DATOS **57**, 113

Treatment; Self-help groups; Alcoholics anonymous; Cocaine; Drug abuse **60**, 169

Treatment; Substance abuse; Cocaine; Homeless; Dual diagnosis **60**, 55

Treatment; Washington State; Employment **60**, 151

Trends; Greece; High-school students; Substance use **58**, 181

Twin study; Drug and alcohol abuse; Genetics **57**, 69

Ultram®; Tramadol HCl; Drug abuse; Drug dependence; Postmarketing surveillance; Controlled Substances Act **57**, 7

Urinalysis; Self-report; Concordance; Validity; Methadone **59**, 43

Urinalysis; Voucher-based reinforcement; Abstinence initiation; Cocaine abuse; Methadone patients; Contingency contracting **58**, 205

Urine testing; Drug abuse; Drug dependence; Heroin; Opiate dependence; Self-report **58**, 111

Validity; DSM-IV dependence; Severity; Assessment; Reliability; Outcome measures **59**, 63

Validity; Urinalysis; Self-report; Concordance; Methadone **59**, 43

Violence; Aggression; Relationships; Alcohol; Drugs **58**, 43

Viral load; HIV; Injection drug users; Drug maintenance treatment; Buprenorphine **60**, 51

Voucher-based reinforcement; Abstinence initiation; Cocaine abuse; Urinalysis; Methadone patients; Contingency contracting **58**, 205

Vouchers; Contingency management; Incentives; Medication management; Compliance; Substance abuse treatment **58**, 9

Washington State; Treatment; Employment **60**, 151

Withdrawal; Benzodiazepine; Convulsive status epilepticus; Flunitrazepam; Lorazepam; Seizures; Side effects **59**, 95

Withdrawal; Cocaine; Human; Outpatient; Drug dependence **59**, 277

Women; Anabolic-androgenic steroids; Abuse; Dependence **60**, 91

Women; IDUs; Crack; HIV **58**, 227

1 year outcomes; Residential treatment; Multiple logistic regression analyses **57**, 89

Young adults; Drug use history; Treatment career; Self-efficacy; Reference group **57**, 151